S&P Futures
3,299.75+36.25(+1.11%)Dow Futures
26,697.00+288.00(+1.09%)Nasdaq Futures
11,247.50+114.75(+1.03%)
Corvus Pharmaceuticals, Inc. (CRVS)
Chart Events
Performance Outlook
| Previous Close | 4.0900 |
| Open | 4.0000 |
| Bid | 0.0000 x 1200 |
| Ask | 0.0000 x 800 |
| Day's Range | 3.7900 - 4.0200 |
| 52 Week Range | 1.0100 - 6.8800 |
| Volume | 413,083 |
| Avg. Volume | 926,320 |
| Market Cap | 106.536M |
| Beta (5Y Monthly) | 2.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5500 |
| Earnings Date | Jul 30, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.60 |
- Zacks
Biotech Stock Roundup: ALXN to Raise Guidance, BMY to Buy MYOK & Other Updates
The biotech sector remains in focus with regulatory, acquisition and other pipeline updates.
- TheStreet.com
Corvus Shares Surge After Positive Data From Early COVID Treatment Study
Burlingame, California-based Corvus Pharmaceuticals said its early-stage coronavirus antibody treatment showed positive results in a Phase one trial, sending shares higher in pre-market trading.
- Benzinga
Looking Into Corvus Pharmaceuticals's Return On Capital Employed
During Q2, Corvus Pharmaceuticals (NASDAQ: CRVS) brought in sales totaling $0.00. However, earnings decreased 18.86%, resulting in a loss of $10.77 million. Corvus Pharmaceuticals collected $0.00 in revenue during Q1, but reported earnings showed a $13.27 million loss.What Is Return On Capital Employed? Changes in earnings and sales indicate shifts in Corvus Pharmaceuticals's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Corvus Pharmaceuticals posted an ROCE of -0.21%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on CRVSROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Corvus Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.In Corvus Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q2 Earnings Insight Corvus Pharmaceuticals reported Q2 earnings per share at $-0.36/share, which did not meet analyst predictions of $-0.28/share.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * 12 Healthcare Stocks Moving In Monday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
